Edgar Filing: AETHLON MEDICAL INC - Form 8-K

AETHLON MEDICAL INC Form 8-K March 21, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 20, 2018

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada 13-3632859

001-37487

(State or other jurisdiction (IRS Employer

(Commission File Number)

of incorporation) Identification Number)

8910 University Center Lane, Suite 660

92122

San Diego, California

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Edgar Filing: AETHLON MEDICAL INC - Form 8-K

Not applicable (Former name on former address if changed since lost report)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by checkmark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
Emerging growth company.
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well as estimates and assumptions made by Registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward-looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although Registrant believes that the expectations reflected in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 8.01 Other Events

On March 20, 2018 the Company participated in an Informational Meeting with the United States Food and Drug Administration (FDA). The meeting was the result of a formal Pre-Submission request that was made by the Company for the purpose of discussing the advancement of the Aethlon Hemopurifier® under an Expedited Access Pathway (EAP) designation that was granted by FDA on September 8, 2017. In October of 2017, FDA provided draft guidance that EAP designated products will subsequently be transitioned to FDA's "Breakthrough Device" program established under the 21st Century Cures Act. The Company will provide further disclosure as it receives material written feedback from FDA.

2

Edgar Filing: AETHLON MEDICAL INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes

James B. Frakes

Dated: March 21, 2018 Chief Financial Officer